Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 89 | 2024 | 5442 | 8.990 |
Why?
|
Graft vs Host Disease | 52 | 2024 | 2957 | 7.240 |
Why?
|
Transplantation Conditioning | 29 | 2023 | 1598 | 2.720 |
Why?
|
Transplantation, Homologous | 25 | 2024 | 4776 | 1.480 |
Why?
|
Leukemia, Myeloid, Acute | 17 | 2023 | 3523 | 1.430 |
Why?
|
Bacteremia | 4 | 2020 | 962 | 1.430 |
Why?
|
Transplantation, Autologous | 10 | 2023 | 2124 | 1.360 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2021 | 314 | 1.350 |
Why?
|
Myelodysplastic Syndromes | 7 | 2022 | 1352 | 1.240 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1832 | 1.060 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2020 | 689 | 0.830 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1620 | 0.780 |
Why?
|
Vitamin A | 1 | 2024 | 615 | 0.750 |
Why?
|
Primary Myelofibrosis | 4 | 2023 | 215 | 0.730 |
Why?
|
Heart Murmurs | 1 | 2020 | 94 | 0.710 |
Why?
|
Bone Marrow | 7 | 2023 | 2948 | 0.710 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 2 | 2020 | 38 | 0.700 |
Why?
|
Erythroid Cells | 1 | 2021 | 238 | 0.700 |
Why?
|
Sarcoma, Myeloid | 1 | 2020 | 59 | 0.690 |
Why?
|
Tacrolimus | 1 | 2022 | 743 | 0.660 |
Why?
|
Central Nervous System Neoplasms | 4 | 2022 | 895 | 0.630 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2021 | 272 | 0.620 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 340 | 0.560 |
Why?
|
Heart Neoplasms | 1 | 2020 | 374 | 0.560 |
Why?
|
Philadelphia Chromosome | 1 | 2016 | 112 | 0.540 |
Why?
|
Lymphoma | 4 | 2022 | 1877 | 0.530 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 1519 | 0.530 |
Why?
|
Humans | 121 | 2024 | 744343 | 0.510 |
Why?
|
Vision Disorders | 1 | 2022 | 1058 | 0.510 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 17 | 0.460 |
Why?
|
Protein Kinase Inhibitors | 4 | 2021 | 5535 | 0.460 |
Why?
|
Feces | 1 | 2019 | 1401 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11524 | 0.460 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2018 | 1381 | 0.450 |
Why?
|
Sarcopenia | 1 | 2018 | 368 | 0.440 |
Why?
|
Iron-Dextran Complex | 1 | 2012 | 14 | 0.430 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1199 | 0.430 |
Why?
|
Nitriles | 3 | 2022 | 956 | 0.420 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2242 | 0.420 |
Why?
|
Steroids | 4 | 2023 | 930 | 0.420 |
Why?
|
Histiocytic Necrotizing Lymphadenitis | 1 | 2012 | 23 | 0.420 |
Why?
|
Microscopic Polyangiitis | 1 | 2012 | 45 | 0.410 |
Why?
|
Clostridium Infections | 1 | 2018 | 548 | 0.410 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 501 | 0.380 |
Why?
|
Bone Marrow Transplantation | 7 | 2021 | 2765 | 0.380 |
Why?
|
Immunotherapy, Adoptive | 5 | 2023 | 1270 | 0.380 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2022 | 1378 | 0.380 |
Why?
|
Immunoconjugates | 1 | 2018 | 901 | 0.380 |
Why?
|
Busulfan | 4 | 2023 | 263 | 0.380 |
Why?
|
Escherichia coli | 2 | 2019 | 4217 | 0.370 |
Why?
|
Acetamides | 2 | 2022 | 249 | 0.370 |
Why?
|
Recurrence | 10 | 2023 | 8340 | 0.360 |
Why?
|
Central Nervous System | 1 | 2017 | 1357 | 0.360 |
Why?
|
Hematinics | 1 | 2012 | 281 | 0.340 |
Why?
|
Adult | 43 | 2023 | 214055 | 0.340 |
Why?
|
Body Composition | 1 | 2018 | 2401 | 0.320 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2540 | 0.320 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2012 | 365 | 0.310 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1738 | 0.310 |
Why?
|
Thiotepa | 2 | 2017 | 66 | 0.310 |
Why?
|
Leukemia | 1 | 2016 | 1511 | 0.310 |
Why?
|
Hematologic Diseases | 2 | 2023 | 498 | 0.310 |
Why?
|
Sarcoidosis | 1 | 2013 | 506 | 0.310 |
Why?
|
Fatal Outcome | 3 | 2019 | 1850 | 0.300 |
Why?
|
Exanthema | 1 | 2012 | 501 | 0.300 |
Why?
|
Leukemia, Plasma Cell | 2 | 2018 | 48 | 0.290 |
Why?
|
Remission Induction | 5 | 2022 | 2386 | 0.290 |
Why?
|
Retrospective Studies | 26 | 2023 | 77449 | 0.290 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1241 | 0.280 |
Why?
|
Middle Aged | 39 | 2024 | 213383 | 0.280 |
Why?
|
Aged | 28 | 2023 | 163280 | 0.260 |
Why?
|
Melphalan | 3 | 2023 | 431 | 0.250 |
Why?
|
Neoplasms, Second Primary | 3 | 2018 | 1061 | 0.240 |
Why?
|
Male | 38 | 2024 | 350118 | 0.240 |
Why?
|
United States Food and Drug Administration | 2 | 2022 | 1584 | 0.240 |
Why?
|
Gastric Bypass | 1 | 2012 | 812 | 0.230 |
Why?
|
Eye Diseases | 2 | 2018 | 669 | 0.220 |
Why?
|
Pyrazoles | 3 | 2023 | 1972 | 0.220 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13695 | 0.210 |
Why?
|
B-Lymphocytes | 1 | 2015 | 4665 | 0.210 |
Why?
|
Vidarabine | 2 | 2023 | 345 | 0.210 |
Why?
|
Female | 37 | 2024 | 380194 | 0.210 |
Why?
|
Acute Disease | 5 | 2023 | 7149 | 0.200 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 97 | 0.200 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 134 | 0.200 |
Why?
|
Young Adult | 16 | 2024 | 56430 | 0.200 |
Why?
|
Quality of Life | 12 | 2024 | 12804 | 0.200 |
Why?
|
Mycophenolic Acid | 2 | 2020 | 343 | 0.190 |
Why?
|
United States | 12 | 2023 | 69872 | 0.190 |
Why?
|
Chimerism | 1 | 2021 | 158 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15165 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.180 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2022 | 419 | 0.180 |
Why?
|
Intestinal Mucosa | 2 | 2023 | 3036 | 0.180 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 8642 | 0.180 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1677 | 0.170 |
Why?
|
Blast Crisis | 2 | 2020 | 103 | 0.170 |
Why?
|
Pyrimidines | 2 | 2021 | 2942 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9239 | 0.170 |
Why?
|
Myeloablative Agonists | 1 | 2019 | 218 | 0.170 |
Why?
|
Whole-Body Irradiation | 1 | 2019 | 449 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 453 | 0.160 |
Why?
|
Hepatic Encephalopathy | 1 | 2019 | 139 | 0.160 |
Why?
|
Ciprofloxacin | 1 | 2020 | 315 | 0.160 |
Why?
|
Premedication | 1 | 2018 | 258 | 0.160 |
Why?
|
Antifungal Agents | 1 | 2022 | 730 | 0.160 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5181 | 0.150 |
Why?
|
Treatment Outcome | 10 | 2023 | 63114 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 290 | 0.150 |
Why?
|
Disease-Free Survival | 5 | 2023 | 6895 | 0.150 |
Why?
|
beta-Lactamases | 1 | 2019 | 306 | 0.150 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 780 | 0.150 |
Why?
|
Immunity, Cellular | 1 | 2023 | 1607 | 0.150 |
Why?
|
Survival Analysis | 4 | 2018 | 10252 | 0.150 |
Why?
|
Thrombopoietin | 1 | 2019 | 225 | 0.150 |
Why?
|
Incidence | 6 | 2023 | 20947 | 0.150 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 606 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.140 |
Why?
|
Tissue Donors | 2 | 2016 | 2240 | 0.140 |
Why?
|
Empathy | 1 | 2021 | 474 | 0.140 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1596 | 0.140 |
Why?
|
Chronic Disease | 5 | 2023 | 9146 | 0.140 |
Why?
|
Mucositis | 1 | 2017 | 101 | 0.140 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 814 | 0.130 |
Why?
|
Antigens, CD34 | 1 | 2017 | 657 | 0.130 |
Why?
|
Hypogonadism | 1 | 2021 | 799 | 0.130 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 804 | 0.130 |
Why?
|
Hospitals, Special | 1 | 2015 | 101 | 0.130 |
Why?
|
Cytarabine | 1 | 2017 | 692 | 0.130 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 639 | 0.130 |
Why?
|
Interferon Type I | 1 | 2018 | 542 | 0.120 |
Why?
|
Infertility | 1 | 2021 | 655 | 0.120 |
Why?
|
T-Lymphocytes | 5 | 2023 | 10180 | 0.120 |
Why?
|
Long-Term Care | 1 | 2018 | 607 | 0.120 |
Why?
|
Dacarbazine | 1 | 2017 | 566 | 0.120 |
Why?
|
Iritis | 1 | 2013 | 17 | 0.120 |
Why?
|
Biological Products | 1 | 2022 | 860 | 0.120 |
Why?
|
Secondary Prevention | 2 | 2018 | 1530 | 0.110 |
Why?
|
Methotrexate | 2 | 2017 | 1727 | 0.110 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2013 | 43 | 0.110 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.110 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 157 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 7913 | 0.110 |
Why?
|
Fetal Blood | 1 | 2019 | 1318 | 0.110 |
Why?
|
Drug Resistance, Bacterial | 1 | 2019 | 1035 | 0.100 |
Why?
|
Pilot Projects | 3 | 2024 | 8324 | 0.100 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.100 |
Why?
|
Azacitidine | 1 | 2013 | 347 | 0.100 |
Why?
|
Child | 7 | 2024 | 77709 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1476 | 0.100 |
Why?
|
Social Support | 1 | 2021 | 2118 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1972 | 0.100 |
Why?
|
Granuloma | 1 | 2013 | 319 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7279 | 0.090 |
Why?
|
Societies, Medical | 2 | 2019 | 3743 | 0.090 |
Why?
|
Antiviral Agents | 1 | 2022 | 2987 | 0.090 |
Why?
|
Body Mass Index | 2 | 2018 | 12720 | 0.090 |
Why?
|
Indoles | 1 | 2018 | 1839 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1415 | 0.090 |
Why?
|
Ferritins | 1 | 2012 | 590 | 0.090 |
Why?
|
Postoperative Care | 1 | 2016 | 1486 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 640 | 0.090 |
Why?
|
Sepsis | 1 | 2023 | 2593 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 3 | 2023 | 1855 | 0.080 |
Why?
|
Antigens, CD19 | 2 | 2022 | 380 | 0.080 |
Why?
|
Prognosis | 7 | 2023 | 29063 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2017 | 1401 | 0.080 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20822 | 0.080 |
Why?
|
Anxiety | 2 | 2020 | 4297 | 0.080 |
Why?
|
Caregivers | 1 | 2020 | 2094 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 9959 | 0.080 |
Why?
|
Survivors | 1 | 2018 | 2291 | 0.080 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2274 | 0.070 |
Why?
|
Sex Factors | 2 | 2018 | 10397 | 0.070 |
Why?
|
Age Factors | 3 | 2018 | 18370 | 0.070 |
Why?
|
Risk Factors | 9 | 2023 | 72290 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2023 | 871 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2538 | 0.070 |
Why?
|
Adolescent | 11 | 2023 | 85781 | 0.070 |
Why?
|
Administration, Oral | 1 | 2013 | 3913 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2015 | 2266 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2459 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2019 | 4245 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4251 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2513 | 0.060 |
Why?
|
Gene Deletion | 1 | 2012 | 2751 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.060 |
Why?
|
Mass Screening | 2 | 2018 | 5255 | 0.060 |
Why?
|
Acetonitriles | 1 | 2023 | 53 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2018 | 5319 | 0.060 |
Why?
|
Depression | 2 | 2020 | 7766 | 0.050 |
Why?
|
Probability | 2 | 2019 | 2505 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7181 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 425 | 0.050 |
Why?
|
Elafin | 1 | 2021 | 33 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39050 | 0.050 |
Why?
|
Time Factors | 4 | 2018 | 40075 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2023 | 257 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11031 | 0.050 |
Why?
|
Obesity, Morbid | 1 | 2012 | 1213 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 264 | 0.050 |
Why?
|
Adaptation, Psychological | 2 | 2024 | 2576 | 0.050 |
Why?
|
Biopsy | 1 | 2013 | 6756 | 0.050 |
Why?
|
Histiocytes | 1 | 2021 | 103 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
rho-Associated Kinases | 1 | 2021 | 279 | 0.050 |
Why?
|
Medicare | 1 | 2018 | 6566 | 0.040 |
Why?
|
Bacterial Translocation | 1 | 2018 | 73 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8663 | 0.040 |
Why?
|
Therapeutics | 1 | 2018 | 116 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 369 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12959 | 0.040 |
Why?
|
Spleen | 1 | 2023 | 2362 | 0.040 |
Why?
|
Fatigue | 1 | 2024 | 1531 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 973 | 0.030 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4149 | 0.030 |
Why?
|
Disease Progression | 2 | 2023 | 13284 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1609 | 0.030 |
Why?
|
Risk Assessment | 3 | 2022 | 23338 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20129 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1275 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12245 | 0.030 |
Why?
|
Checklist | 1 | 2021 | 833 | 0.030 |
Why?
|
Advisory Committees | 1 | 2018 | 775 | 0.030 |
Why?
|
Survival Rate | 2 | 2018 | 12788 | 0.030 |
Why?
|
Canada | 1 | 2018 | 2065 | 0.030 |
Why?
|
Inpatients | 1 | 2024 | 2518 | 0.030 |
Why?
|
Europe | 1 | 2018 | 3339 | 0.030 |
Why?
|
Regression Analysis | 1 | 2021 | 6459 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2670 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 2008 | 0.020 |
Why?
|
Palliative Care | 1 | 2024 | 3493 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 35421 | 0.020 |
Why?
|
Graft Rejection | 1 | 2021 | 4397 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2018 | 25625 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4201 | 0.020 |
Why?
|
Patient Care Team | 1 | 2018 | 2531 | 0.020 |
Why?
|
Mutation | 2 | 2023 | 29786 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7785 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4669 | 0.020 |
Why?
|
Infant | 2 | 2018 | 35136 | 0.020 |
Why?
|
Child, Preschool | 2 | 2018 | 41006 | 0.020 |
Why?
|
Hospitalization | 1 | 2024 | 10262 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12354 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7322 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14557 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2021 | 4266 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10638 | 0.010 |
Why?
|
Pain | 1 | 2017 | 4986 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8388 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15226 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18029 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13881 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15295 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57776 | 0.010 |
Why?
|
Cohort Studies | 1 | 2017 | 40561 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81183 | 0.010 |
Why?
|
Neoplasms | 1 | 2020 | 21683 | 0.010 |
Why?
|
Animals | 1 | 2018 | 168757 | 0.000 |
Why?
|